Takeda Pharmaceutical (TAK) Accounts Payables (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Accounts Payables of $2.8 billion for Q2 2026, down 3.73% year-over-year from $2.9 billion in Q2 2025, and down 10.53% quarter-over-quarter from $3.1 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Accounts Payables (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Accounts Payables history runs 10 years deep, the most recent figure standing at $2.8 billion for Q2 2026.
- In Q2 2026, Accounts Payables fell 3.73% year-over-year to $2.8 billion; the TTM figure through Jun 2026 stood at $2.8 billion (down 3.73% YoY), while the FY2026 annual figure was $3.3 billion, up 4.56% from the prior year.
- Accounts Payables for Q2 2026 stood at $2.8 billion, down from $3.1 billion in the prior quarter.
- The five-year high for Accounts Payables was $4.9 billion in Q1 2023, with the low at $2.7 billion in Q4 2022.
- The 5-year median for Accounts Payables is $3.0 billion (2024), against an average of $3.2 billion.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables jumped 36.76% in 2022, then fell 24.73% in 2024.
- Takeda Pharmaceutical's Accounts Payables stood at $2.7 billion in 2022, then gained by 21.3% to $3.3 billion in 2023, then slipped by 7.49% to $3.0 billion in 2024, then gained by 0.38% to $3.0 billion in 2025, then dropped by 7.74% to $2.8 billion in 2026.
- Business Quant data shows TAK's Accounts Payables at $2.8 billion in Q2 2026, $3.1 billion in Q1 2026, and $3.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 356.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 332.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.80 Bn |
| Mar 31, 2026 | 3.13 Bn |
| Dec 31, 2025 | 3.04 Bn |
| Sep 30, 2025 | 2.98 Bn |
| Jun 30, 2025 | 2.91 Bn |
| Mar 31, 2025 | 3.12 Bn |
| Dec 31, 2024 | 3.03 Bn |
| Sep 30, 2024 | 2.77 Bn |
| Jun 30, 2024 | 3.01 Bn |
| Mar 31, 2024 | 3.69 Bn |
| Dec 31, 2023 | 3.27 Bn |
| Sep 30, 2023 | 2.92 Bn |
| Jun 30, 2023 | 3.22 Bn |
| Mar 31, 2023 | 4.91 Bn |
| Dec 31, 2022 | 2.70 Bn |
| Sep 30, 2022 | 2.81 Bn |
| Jun 30, 2022 | 3.28 Bn |
| Mar 31, 2022 | 4.44 Bn |
| Dec 31, 2021 | 3.09 Bn |
| Sep 30, 2021 | 3.06 Bn |